FDA staff flags eye safety risks for GSK's blood cancer drug – Reuters

1. FDA staff flags eye safety risks for GSK’s blood cancer drug  Reuters
2. US Return Of GSK’s Blenrep Threatened By Ocular Toxicity, Dosage Optimization Questions  insights.citeline.com
3. GSK lower after FDA briefing documents for myeloma drug  TipRanks
4. Recon: FDA reviewers flag eye risks with GSK’s blood cancer therapy; FDA ends import screening exemption for low-value goods  Regulatory Affairs Professionals Society | RAPS
5. Fate of Myeloma Drug’s Comeback Now Rests in Hands of FDA Panel  MedPage Today

Continue Reading